Konyang University Hospital in South Korea relies on Molecular Health’s MH Guide for personalized cancer medicine

HEIDELBERG, GERMANY / DAEJEONG, SOUTH KOREA – Media
OutReach – 16 July 2021 – Konyang
University Hospital in Daejeong, South Korea, will rely on MH Guide in the
personalized treatment of its cancer patients. This is the result of an
agreement between the hospital and Molecular Health. It makes Konyang
University Hospital the first facility in South Korea to use MH Guide.
“Precision medicine in cancer care enables personalized treatment through
comprehensive analysis of genes, clinical information and drugs. With our NGS
system and MH Guide, we have a complete precision medicine ecosystem that will
enable us to provide world-class cancer care,” said Yoon Dae-seong, Director
of the Cancer Center at Konyang University Hospital.

MH Guide is an analysis
software that helps molecular pathologists and oncologists interpret NGS data
and make treatment decisions. The software automatically detects relevant gene
variants from molecular information and identifies treatment options based on
the molecular profile and ongoing trials that may be relevant to the patient.
To do this, MH Guide matches molecular patient data with data derived from one
of the largest growing and Molecular Health-owned knowledge platforms (Dataome).
This makes MH Guide an evidence-based decision support tool that enables
physicians and molecular pathologists to keep pace with the rapidly growing stock
of medical knowledge and make it actionable in treating their patients.

“We are
very pleased to collaborate with Konyang University Hospital. We are convinced
that with MH Guide we can make an important contribution to the personalized
care for Korean patients,” said Stephan Hettich, SVP, Head of Sales &
Business Development, APAC, at Molecular Health.